Kimia Biosciences share news and announcements
BSE: 530313Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹30.05.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹142 Cr2,580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 19.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 8.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 51.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 19.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 1.95
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,361
Kimia Biosciences share news and announcements
546 announcements, routine notices left out, newest first. Page 4 of 11.
Apr 2024
19 Apr · Compliance Certificate Pursuant To Regulation 40(9) Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015.
10 Apr · Certificate Under Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulations, 2015.
10 Apr · Intimation Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For Written Confirmation For Active Substances Imported Into The European Union (EU) For Medical Products For Human Use.
Mar 2024
4 Mar · Intimation Under Regulation 30 For Written Confirmation For Active Substances Imported Into The European Union (EU) For Medicinal Products For Human Use.
Feb 2024
7 Feb · Board meeting
Meeting on 14 Feb 2024: quarterly results
Dec 2023
29 Dec · Intimation Regarding Withdrawing The Contribution In The LLP.
Nov 2023
9 Nov · Comments Of Board Of Directors On Non- Compliance Of Regulation 34 Of SEBI Listing Regulations, 2015.
4 Nov · Intimation Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
1 Nov · Board meeting
Meeting on 9 Nov 2023: quarterly results
Oct 2023
5 Oct · Intimation Regarding Incorporation Of Limited Liability Partnership.
Sep 2023
30 Sep · Intimation Of Regularization Of Non- Executive Non- Independent Director Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations,
5 Sep · Board meeting
Meeting on 5 Sep 2023: annual general meeting
Aug 2023
14 Aug · Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations 2015.
7 Aug · Board meeting
Meeting on 14 Aug 2023: quarterly results
Jul 2023
14 Jul · Intimation Under Regulation 30 Of International Application Published Under Patent Cooperation Treaty (PCT).
Jun 2023
May 2023
23 May · Board meeting
Meeting on 30 May 2023: audited results
Apr 2023
7 Apr · Compliance Certificate Under Regulation 7(3) SEBI (Listed Obligations And Disclosure Requirements) Regulations, 2015.
7 Apr · Submission Of Compliance Certificate Under Regulation 40(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
Mar 2023
7 Mar · Intimation Under Regulation 30 For Approval Of Advance Authorisation.
Feb 2023
6 Feb · Board meeting
Meeting on 14 Feb 2023: quarterly results
Jan 2023
4 Jan · Intimation Of Transmission Of 16 Equity Shares.
Nov 2022
24 Nov · Intimation Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
4 Nov · Board meeting
Meeting on 14 Nov 2022: quarterly results
Oct 2022
11 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0